Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
The FDA has granted Breakthrough Device designation to the iLet Bionic Pancreas System, a wearable device designed to autonomously control blood sugar levels in patients with diabetes and other conditions.
The vaginal ring releases on average 0.12mg/d of etonogestrel, a progestin, and 0.015mg/d of ethinyl estradiol, an estrogen.
Linzagolix is a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, the trial assessed the treatment in 535 women.
Insulin glargine 300 U/mL was found to be comparable to insulin glargine 100 U/mL in providing effective glycemic control in pediatric patients with type 1 diabetes.
The Company is currently conducting a comparative study with the aim of having the treatment designated as a therapeutic equivalent to Forteo.
The FDA has expanded the approval of Crysvita (burosumab; Ultragenyx and Kyowa Kirin) to include treatment in pediatric patients as young as 6 months with X-linked hypophosphatemia.
Patients taking the analgesic tramadol have an increased propensity for hypoglycemia compared to other opioids, according to a new analysis of the Food and Drug Administration’s Adverse Event Reporting Systems.
The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) as a possible treatment to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease.
The FDA has granted 510(k) market clearance to the OneDraw A1C Test system, which monitors HbA1c levels in individuals with diabetes for long-term glucose control.
